SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or “the Firm”), a medical stage biotechnology firm engaged within the discovery and improvement of first-in-class medicines from its proprietary tRNA synthetase platform, right now introduced that it has entered right into a analysis settlement with Stanford Medication. Michael Lim, M.D., Chair of the Division of Neurosurgery at Stanford Medication, will function the principal investigator for the research. Dr. Lim’s analysis focuses on understanding the fundamental mechanisms of immunosuppression in glioblastoma multiforme (GBM).
“We all know that the immune system performs an vital position in GBM recurrence, and now we have studied stimulating myeloid cells as a technique to reverse immunosuppression within the tumor microenvironment,” stated Dr. Lim. “We sit up for wanting on the position through which anti-neuropilin-2 (NRP2) antibodies together with different therapies could play in reactivating the immune system with a purpose to cut back tumor recurrence.”
The analysis collaboration goals to discover the position of the Firm’s novel operate blocking antibodies towards NRP2 together with chemotherapy to guage their position in reversing immune evasion in GBM. If preliminary research are profitable, the researchers plan to guage the NRP2 antibodies together with different immunomodulating brokers, comparable to anti-PD-1, STING, or anti-CSF-1R, to handle a number of targets of myeloid and T cell immunosuppression for the potential therapy of GBM.
“We’re happy to provoke this analysis collaboration with Stanford Medication and Dr. Lim, a frontrunner in immunotherapy for mind tumors, to discover the potential for mixture remedy with NRP2-targeted antibodies in GBM,” stated Sanjay S. Shukla, M.D., M.S., President and Chief Govt Officer of aTyr. “Whereas we’re targeted on advancing our tRNA synthetase derived therapies, we consider NRP2 could play an vital but largely underappreciated position in immune cross speak in lots of cancers, together with GBM. This research presents an vital alternative to boost our mechanistic understanding relating to the position of NRP2 in mediating immune suppression in an especially aggressive most cancers the place there’s a excessive unmet medical want.”
GBM is a fast-growing and aggressive mind tumor that invades the close by mind tissue however doesn’t sometimes unfold to different organs. GBM can lead to demise in lower than 6 months. Present commonplace of care consists of surgical procedure adopted by radiation and chemotherapy, which might lengthen survival however just isn’t healing and the speed of recurrence is excessive. Analysis that explores the underlying causes and mechanism of recurrence could result in new remedies that may deal with and assist handle recurrence, that are vastly wanted.
About aTyr
aTyr is a medical stage biotechnology firm leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and irritation. tRNA synthetases are historic, important proteins which have advanced novel domains that regulate various pathways extracellularly in people. aTyr’s discovery platform is targeted on unlocking hidden therapeutic intervention factors by uncovering signaling pathways pushed by its proprietary library of domains derived from all 20 tRNA synthetases. aTyr’s lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in medical improvement for the therapy of interstitial lung illness, a bunch of immune-mediated problems that may trigger irritation and progressive fibrosis, or scarring, of the lungs. For extra data, please go to www.atyrpharma.com.
Ahead-Trying Statements
This press launch accommodates forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995. Ahead-looking statements are normally recognized by means of phrases comparable to “goal,” “anticipate,” “believes,” “designed,” “can,” “expects,” “intends,” “could,” “alternative,” “plans,” “potential,” “will,” and variations of such phrases or related expressions. We intend these forward-looking statements to be coated by such protected harbor provisions for forward-looking statements and are making this assertion for functions of complying with these protected harbor provisions. These forward-looking statements embody, amongst others, statements relating to the potential therapeutic advantages and purposes of NRP2 antibodies; timelines, plans and anticipated outcomes with respect to sure analysis and improvement actions and the anticipated personnel concerned in such actions; potential advantages of collaborations; and sure improvement objectives. These forward-looking statements additionally mirror our present views about our plans, intentions, expectations, methods and prospects, that are based mostly on the knowledge presently obtainable to us and on assumptions now we have made. Though we consider that our plans, intentions, expectations, methods and prospects, as mirrored in or advised by these forward-looking statements, are affordable, we can provide no assurance that the plans, intentions, expectations, methods or prospects shall be attained or achieved. All forward-looking statements are based mostly on estimates and assumptions by our administration that, though we consider to be affordable, are inherently unsure. Moreover, precise outcomes could differ materially from these described in these forward-looking statements and shall be affected by quite a lot of dangers and elements which might be past our management together with, with out limitation, uncertainty relating to geopolitical and macroeconomic occasions, dangers related to the invention, improvement and regulation of our product candidates, the dangers inherent in research of potential medical therapies, the chance that we or our companions could stop or delay preclinical or medical improvement actions for any of our current or future product candidates for quite a lot of causes (together with difficulties or delays in affected person enrollment in deliberate medical trials), the chance that current collaborations may very well be terminated early, and the chance that we could not be capable of increase the extra funding required for our enterprise and product improvement plans, in addition to these dangers set forth in our most up-to-date Annual Report on Kind 10-Ok, Quarterly Experiences on Kind 10-Q and in our different SEC filings. Besides as required by regulation, we assume no obligation to replace publicly any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Contact:
Ashlee Dunston
Director, Investor Relations and Public Affairs
adunston@atyrpharma.com
